Equities

Athira Pharma Inc

ATHA:NSQ

Athira Pharma Inc

Actions
  • Price (USD)0.6591
  • Today's Change0.017 / 2.62%
  • Shares traded461.37k
  • 1 Year change-55.47%
  • Beta2.9356
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform0
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Athira Pharma Inc have a median target of 0.55, with a high estimate of 0.600 and a low estimate of 0.50. The median estimate represents a -16.55% decrease from the last price of 0.6591.
High-9.0%0.600
Med-16.6%0.55
Low-24.1%0.50

Earnings history & estimates in USD

On Nov 07, 2024, Athira Pharma Inc reported 3rd quarter 2024 losses of -0.75 per share.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate+3.15%
Athira Pharma Inc reported annual 2023 losses of -3.09 per share on Feb 22, 2024.
Average growth rate-25.90%
More ▼

Revenue history & estimates in USD

Athira Pharma Inc did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Athira Pharma Inc did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.